As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), ...

Valentine’s Day represents a perfect opportunity to highlight news and updates from across biopharma that have hearts a | ...

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with ...

A crucial challenge in AI today is bridging the gap between general intelligence and deep, organisation-specific knowledge.

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® (iptacopan capsules) as ...

The Trump administration's decision to pause enforcement of an anti-bribery law raised the specter that drugmakers could ...

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

Yuhan Corporation announced on the 11th that the allergy drug candidate "YH35324," introduced from GI Innovation, has demonstrated superior therapeutic effects compared to Novartis' "Xolair ... Class ...

The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...